News from senhwa biosciences, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Dec 23, 2020, 21:40 ET Senhwa Biosciences Receives US FDA 'Study May Proceed' Letter to Treat BRCA2+ or PALB2+ Solid Tumors With CX-5461

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics...

Dec 13, 2020, 21:09 ET Senhwa Biosciences's Positive Topline Cholangiocarcinoma Data Abstract Accepted by 2021 ASCO Gastrointestinal Cancers Symposium

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics...

Dec 03, 2020, 09:17 ET Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics...

Nov 25, 2020, 21:34 ET Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics...

Nov 06, 2020, 09:00 ET CARE GA Receives Study May Proceed Letter from US FDA to Initiate Phase II Clinical Trial of Senhwa's Silmitasertib in COVID-19 Patients

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics...

Nov 02, 2020, 09:00 ET Senhwa Announces Multiple IND application submissions to U.S. FDA for Silmitasertib as a Potential Treatment for COVID-19

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics...

Sep 11, 2020, 20:34 ET Coronavirus Breakthrough: Senhwa Reports First eIND Silmitasertib Treated Severe COVID-19 Patient - Discharged Following Five Days of Treatment

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics...

Jul 07, 2020, 09:00 ET Senhwa Biosciences's Silmitasertib Receives Rare Pediatric Disease Designation from U.S. FDA for Treatment of Recurrent Sonic Hedgehog Medulloblastoma

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on Next Generation DNA Damage Response (DDR) therapeutics...

Jul 01, 2020, 09:00 ET Coronavirus Breakthrough: New Study Highlights Senhwa Biosciences Silmitasertib as Potential Treatment for COVID-19

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on Next Generation DNA Damage Response (DDR) therapeutics...

Mar 31, 2020, 07:00 ET Senhwa Biosciences Silmitasertib Named as Potential COVID-19 Therapy

Senhwa Biosciences, Inc. (TPEx: 6492) announced today that its drug Silmitasertib (CX-4945) was determined to be a potential treatment for COVID-19....

Dec 12, 2019, 15:00 ET Senhwa Biosciences Reports Positive Phase 1 Data of CX-5461 in Patients With Advanced Solid Tumors at 2019 SABCS

Senhwa Biosciences Inc. (TPEx: 6492), a clinical stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics...

Apr 17, 2019, 07:00 ET Senhwa Biosciences Silmitasertib / Basal Cell Carcinoma Trial Completed 1st Patient Enrollment

Senhwa Biosciences, Inc. (TPEx: 6492) announced today that the clinical trial of Silmitasertib (CX-4945) for the treatment of Basal Cell Carcinoma...

Nov 01, 2018, 01:30 ET Senhwa Biosciences Silmitasertib filed IND of Basal Cell Carcinoma approved by FDA

Senhwa Biosciences Inc. (TPEx: 6492) announced today that FDA has approved its IND application for basal cell carcinoma (BCC). To accelerate the...

Jun 12, 2018, 09:00 ET PBTC and Senhwa sign cooperation agreement to develop CX-4945 for pediatric brain tumor treatment

Senhwa Biosciences Inc. (6492.TT) announced that the company and the Pediatric Brain Tumor Consortium (PBTC, US, www.pbtc.org) have signed a clinical ...

Jan 04, 2017, 09:00 ET Senhwa Biosciences CX-4945 Granted Orphan Drug Designation by the US FDA in Cholangiocarcinoma

Senhwa Biosciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CX-4945 for the...

Dec 14, 2016, 09:00 ET Senhwa Biosciences Appoints Lucas S. Chang as General Counsel

Senhwa Biosciences, Inc. announced the appointment of Lucas S. Chang as Vice President - General Counsel today. Lucas S. Chang has assumed the role...

Dec 06, 2016, 09:00 ET Senhwa CX-4945 Phase I Clinical Trial Results Accepted for Presentation at the 2017 ASCO Gastrointestinal Cancers Symposium

Senhwa Biosciences, Inc., a leading company in developing novel small molecule targeted therapy and drugs, announced that it will publish the Phase I ...